|
“ "Capital-E has been an enabling partner to make Excico become real. They have been very supportive and their knowledge of the industry and business practices is a real asset. Obviously, the decision of Capital-E to invest brought credibility in front of our customers. The whole team at Excico values highly the backing from Capital-E and they will be key to our success moving forward" Dominique Berard, CEO of Excico ” |
| PHARMA DIAGNOSTICS |
|
Pharma Diagnostics develops a unique drug discovery screening technology based on localised surface plasmon resonance and noble metal nanoparticles in solution. The platform is high throughput, highly sensitive, label-free and requires no specialist instrumentation/hardware. It is particularly relevant to fragment screening and antibody screening. Responsible: Marc Wachsmuth
|
